Hjem › Eggstokkreft › Alabama
Kliniske studier for Eggstokkreft i Alabama
27 studier for Eggstokkreft søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564377A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
- Usa Mitchell Cancer Institute /ID# 276022, Mobile
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0170-USA Mitchell Cancer Institute, Mobile
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05128825DESTINY-PANTUMOUR04
- Research Site, Birmingham
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Kvinner · Oppdatert 25. sep. 2026 · NCT03564340A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Alabama - Birmingham ( Site 0058), Birmingham
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 17. sep. 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Usa Health Mitchell Cancer Institute, Mobile
RekruttererFase 2
Alder 18 til 99 · Kvinner · Oppdatert 15. sep. 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 14. sep. 2026 · NCT06787612FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The University of Alabama, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06303505Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Alabama at Birmingham ( Site 0006), Birmingham
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- The University of South Alabama, Mitchell Cancer Institute, Mobile
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 26. aug. 2026 · NCT05281471Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119Study of NTB-928 in R/R OC
- The University of Alabama, Birmingham
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 20. aug. 2026 · NCT07690189A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 til 99 · Kvinner · Oppdatert 29. jul. 2026 · NCT03538665Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 16. jul. 2026 · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 14. jul. 2026 · NCT04606914Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. jun. 2026 · NCT05952453Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT05297734SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.